Skip to content
Review Open access

Neuroinflammation in Alzheimer’s disease-associated sensory dysfunction: mechanistic links, actionable targets and therapeutic strategies

Jul 2026 · Frontiers in Aging Neuroscience · Vol 18 · 0 citations · 136 references
Medicine

TL;DR

This work aimed to identify AD-related olfactory and visual or retinal abnormalities, combine core inflammatory pathways and their interactions with amyloid-β and tau pathology, and summarize actionable targets and candidate interventions along a “receptor–intracellular signaling-inflammasome-effector” axis, to inform earlier-stage detection and mechanism-guided intervention in AD.

Abstract

Alzheimer’s disease (AD) is the most common cause of dementia and major public-health challenge in aging societies worldwide. Accumulating evidence suggests that olfactory and visual deficits can precede overt cognitive symptoms and are closely associated with amyloid-β deposition, pathological tau phosphorylation, and disease progression. Early sensory abnormalities in AD likely arise from converging pathological processes. Among these, chronic neuroinflammation marked by microglial and astrocytic reactivity, inflammasome activation and increased pro-inflammatory mediators might play a pivotal role linking sensory-circuit injury to neurodegeneration. A coherent synthesis of the inflammatory mechanisms underlying early olfactory and visual impairment in AD remains limited, and putative molecular pathways and interventions have not been fully integrated. We aimed to identify AD-related olfactory and visual or retinal abnormalities, combine core inflammatory pathways and their interactions with amyloid-β and tau pathology, and summarize actionable targets and candidate interventions along a “receptor–intracellular signaling-inflammasome-effector” axis, to inform earlier-stage detection and mechanism-guided intervention in AD.

Read PDF

Similar papers

Review Aug 2026

Neuroinflammatory and molecular pathways in Alzheimer’s disease: mechanistic crosstalk and emerging therapeutic opportunities

Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.

Abhay Thakur, Rohit Sharma, Sneha Kumari et al. · 0 citations
Review Open access Aug 2026

The NLRP3 Inflammasome and Pro-Inflammatory Cytokines in Alzheimer's Disease: Molecular Mechanisms, Neuroimmune Crosstalk, Biomarkers, and Emerging Therapeutic Perspectives

The molecular mechanisms underlying NLRP3 inflammasome activation in Alzheimer’s disease, its interaction with pro-inflammatory cytokine networks, and the emerging role of inflammasome-related biomarkers in disease characterization are examined.

Hira Shabbir · 0 citations
Review Open access Aug 2026

Microglia-mediated neuroinflammation in Alzheimer’s disease: mechanisms and emerging therapeutic targets

A “cellular state–pathological network–therapeutic window” framework is proposed and the roles of microglia in amyloid-β plaque seeding and compaction, NLRP3 inflammasome activation, mitochondrial DNA–cGAS–STING signaling, complement-mediated synaptic engulfment, and bidirectional microglia–tau feedback are systematica...

Lian-Jing Xu, Ying Zhang, Li Jiang et al. · 0 citations
Review Open access Aug 2026

Mechanisms, Biomarkers and Therapeutic Implications of Neuroinflammation in Alzheimer's Disease

The dual and stage‐dependent roles of microglia and astrocytes are explored, discussion of blood–brain barrier dysfunction and peripheral immune infiltration as underappreciated pathogenic contributors are expanded, and emerging evidence linking neuroinflammation specifically to tau pathology is integrated.

S. Papelian · 0 citations
Review Jul 2026

Targeting the NLRP3 Inflammasome in Alzheimer's Disease: Mechanistic Insights and Therapeutic Advances.

This review regards NLRP3 inflammasome as a critical inflammatory hub and a promising target for disease-modifying therapy in AD, and provides useful perspectives on AD pathogenesis to inform the development of more rational therapeutic strategies.

Wenwen Lian, Fulin Zhou, Zhuohang Tong et al. · 0 citations
Review Open access Sep 2026

Alzheimer’s Disease in the Era of Geroscience: Mechanisms, Biomarkers, and Therapeutic Prospects

Alzheimer’s disease (AD) is the leading cause of dementia and a heterogeneous neurodegenerative disorder characterized by amyloid-β (Aβ) and tau pathology, impaired proteostasis, neurovascular dysfunction, maladaptive glial and immune responses, and synaptic dysfunction. Human genetic evidence supports an upstream role...

P. Chmielewski · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.